Modulation of the Rat Hepatic Cytochrome P4501A Subfamily Using Biotin Supplementation

Table 1

Evaluation of the mutagenicity of the S9 fraction that was obtained from rats that were treated with biotin in the Ames test.

Day	Chemical	Dose (𝜇g/plate)	Number of His^+ revertants/plate^(a)
			B−^(b)	B+^(c)	Positive control^(d)
1	B[a]P	0	23±5	18±1	28±6
		1	55±17	55±8	59±6
		5	229±104	210±59	433±143
		10	215±67	220±61	557±86
		20	304±49	281±30	913±144
		Induced revertants/𝜇g^(e)	40.5	52.7	62.3*
7	B[a]P	0	49±8	62±10	66±7
		1	68±7	66±8	81±27
		5	132±7	137±20	300±29
		10	114±17	128±8	436±99
		20	148±31	159±15	773±127
		Induced revertants/𝜇g^(e)	16.5	15.0	37.4*

(a)The mean number of revertant colonies identified in three replicates in two independent experiments.
^(b)The liver S9 fraction from control rats.
^(c)The liver S9 fraction from biotin-treated rats (2 mg/kg).
^(d)The liver S9 fraction from phenobarbital-treated rats (60 mg/kg). 𝛽-naphthoflavone (80 mg/kg) was used as a positive control.
^(e)The slope at the origin was calculated using the SALANAL software program.
*Significantly different from B− and B+ (𝑃≤0.05), as assessed using Student’s 𝑡-test.